SinABiomedics

SinABiomedics is a German biotechnology company specializing in precision oncology and immunology, with a primary focus on Chronic Lymphocytic Leukemia (CLL). The company utilizes its proprietary R110 biomarker platform, centered on the IGLV3-21R110 mutation of the B-cell receptor, to develop targeted diagnostics and therapies. Their lead programs include a diagnostic monoclonal antibody (SIN-A-1001) for precise patient stratification and a first-in-class tumor-specific CAR-T cell therapy designed to selectively eliminate cancer cells while preserving the healthy immune system. Beyond hematology, SinABiomedics is leveraging its antibody-mediated immune modulation platform to develop treatments for a broad spectrum of autoimmune diseases. The company's research is supported by significant funding from the German Federal Ministry of Education and Research (BMBF) and collaborations with leading academic institutions.